Robert Andtbacka

[Robert Andtbacka @RobertAndtbacka]

I am thrilled to join the #HiFiBiO team as Chief Medical Officer. I am deeply impressed by HiFiBiO’s innovative approach to developing novel #immune therapies. Together we will advance groundbreaking therapies, providing improved disease treatments and renewed hope for #patients.

[HiFiBiO Therapeutics @hifibio]

Welcome Robert Andtbacka to the HiFiBiO family as our new Chief Medical Officer!

Dr. Andtbacka will lead the company's clinical activities and collaborate with the leadership team to drive the company’s extensive pipeline and overall company strategy.

https://t.co/Z2C0Tq0u2p

[7and8biopharma @7and8biopharma]

@7and8biopharma reaches a new clinical development milestone for BDB001 monotherapy: First Patient Treated in a Phase 2 Clinical Trial in anti-PD-1 / anti-PD-L1 Refractory Solid Tumors.

Full Release: https://t.co/lzPPj41ipD
#immunotherapy #cancer #oncology #TLR78 #BDB001

[7and8biopharma @7and8biopharma]

We are happy to announce an abstract detailing interim data for BDB001 in combination with pembrolizumab was accepted for a poster discussion presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. https://t.co/lQgVtF6Adr

[Robert Andtbacka @RobertAndtbacka]

Just released New Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST https://t.co/t5A3RK98BY…. @greg_goldmacher @AnuradhaK_MD @jasonlukemd ⁦@dcmadoff⁩ #itRECIST #oncology #intratumoral #Immunotherapy https://t.co/Y3RnrfnM91

[Robert Andtbacka @RobertAndtbacka]

Seven and Eight Biopharmaceuticals Inc. reaches important milestone with clinical collaboration with Merck (MSD). The safety and anti tumor activity of BDB001, a novel TLR 7/8 agonist, will be studied in combo with pembrolizumab in pts with solid tumors.https://t.co/65Of0kxFXX

[Robert Andtbacka @RobertAndtbacka]

Fantastic meeting in Iaşi Romania #updatesinoncology

[Robert Andtbacka @RobertAndtbacka]

T-VEC approved for metastatic melanoma. A good day for patients

https://t.co/yvbk8yyyQ9

[Robert Andtbacka @RobertAndtbacka]

Welcome to Huntsman Immunotherapy conference on Saturday. http://t.co/XSfYibIlQy

[Omid Hamid MD @OmidHamidMD]

Thanks presenters @RobertAndtbacka, Carvajal @columbiacancer, Hoffner,Postow @MSKCC_OncoNotes , Faries @JohnWayneCI

[Robert Andtbacka @RobertAndtbacka]

@OmidHamidMD @Amgen yes Omid, it never stops. #lovethepatientsacceptthehours

[Omid Hamid MD @OmidHamidMD]

All about #TVEC and @Amgen desire to get #oncolytic therapy approved
http://t.co/Becbfpevad

[Punit Dhillon @PunitDhillon]

FDA Panels Support Approval of T-VEC in Melanoma $amgn https://t.co/goEzdy2YoS via @OncLive | this is great news for IT immunotherapy! $oncs

[Robert Andtbacka @RobertAndtbacka]

Exciting news about Cavatak presented at AACR. http://t.co/LyEFSsfwwI